High Serum Alkaline Phosphatase Flare after First-Line Androgen Deprivation Therapy Predicts Poor Prognosis in Metastatic Prostate Cancer Patients Treated with Second-Generation Androgen Receptor Targeted Therapy

Table 1

Baseline characteristics of patients treated with ART and docetaxel.

Variables	ART	Docetaxel
Number of patients	35	17
Age (years)	75 (60–92)	67 (56–89)	0.0149
Clinical stage T2	2	0	0.46
T3	14	6
T4	19	11
Visceral metastasis	5	1	0.63
Gleason score ≤8	14	9	0.44
Gleason score ≥9	21	8
PSA (ng/mL)	472 ± 497	277 ± 701	0.98
LDH (U/L)	218 ± 22	187 ± 15	0.22
ALP (U/L)	513 ± 249	617 ± 154	0.65
Hemoglobin (g/dL)	13.6 ± 0.3	14.1 ± 0.5	0.79
Calcium (mg/dL)	9.1 ± 0.09	9.1 ± 0.14	0.63
Testosterone (ng/mL)	3.5 ± 0.25	3.8 ± 0.38	0.55
PSA nadir (ng/mL)	0.66 ± 3.11	1.36 ± 4.33	0.95
Follow-up duration (months)	45.3 ± 4.7	34.0 ± 5.5	0.21

ART: androgen receptor targeted therapy, PSA: prostate-specific antigen, LDH: lactate dehydrogenase, ALP: alkaline phosphatase.